PHARMACEUTICALS
Untitled Page
Aliso Viejo's Valeant plans to buy Polish dermatology products
The deal will cost $18 million.
By Kristen SchottPublished: October 30, 2009 10:01 AM
Aliso Viejo-based Valeant Pharmaceuticals International plans to acquire the rights to a number of prescription and cosmetic dermatology products from an unnamed Polish firm. The deal will cost $18 million.
The products hold $8 million in yearly sales, and the move is expected to boost Valeant's work to expand its dermatology product line, according to the company.
"We continue to focus our development efforts in building leading dermatology franchises in each of our select regions," says J. Michael Pearson, chairman and CEO of the firm.
He says the newest agreement adds prescription and cosmetic products to the company's portfolio in Central Europe, and it is also expected to increase Valeant's reach to dermatologists in the areas.
NEXT PAGE >>
Related headlines
Irvine-based Fisker set to buy Delaware plant
Ingram Micro acquires ComputaCenter Distribution
Grubb & Ellis announces $90 million preferred equity transaction
|
||||
|
The products hold $8 million in yearly sales, and the move is expected to boost Valeant's work to expand its dermatology product line, according to the company. "We continue to focus our development efforts in building leading dermatology franchises in each of our select regions," says J. Michael Pearson, chairman and CEO of the firm. He says the newest agreement adds prescription and cosmetic products to the company's portfolio in Central Europe, and it is also expected to increase Valeant's reach to dermatologists in the areas. NEXT PAGE >> Related headlines Irvine-based Fisker set to buy Delaware plant Ingram Micro acquires ComputaCenter Distribution Grubb & Ellis announces $90 million preferred equity transaction |
||||
